Open AccessCOUMARIN (ESCULETIN) - AN ANTIRHEUMATOID ARTHRITIC COMPOUND: AN UPDATE
Author(s) -
Jaya Kumari S
Publication year - 2018
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2018.v11s4.31710
Subject(s) - chemistry , arthritis , pharmacology , antioxidant , reactive oxygen species , coumarin , enzyme , polyphenol , reactive nitrogen species , lipoxygenase , nitric oxide , tyrosinase , biochemistry , medicine , immunology , organic chemistry
Context: Esculetin is a natural polyphenolic compound. It is chemically 6,7-dihydroxycoumarin and one of the ingredients of Cortex fraxini, a Chinese traditional medicine. It is used as a dietary supplement and found as non-toxic. Recently, there are many research works evaluated on esculetin in arthritis with supported molecular mechanisms.Objectives: Esculetin becoming more attractive prodrug for arthritis. Hence, the present minireview will consolidate the targeted site of esculetin in the treatment of arthritis over the past decade.Results: The most important molecular mechanism of esculetin is an antioxidant activities with decreased level of reactive oxygen species/reactive nitrogen species. It also inhibited lipoxygenase 5, lipoxygenase 12, and tyrosinase enzymes. It reduces the inflammation by modulating the key inflammatory enzyme matrix metalloproteinase-1 activity. It also lowers the nitrous oxide and prostaglandin E2 level in synovial fluid. Esculetin derivatives such as 5-methoxy esculetin inhibited the activity of nitrogen-activated protein kinases. The updated data also reveal that esculetin suppresses the leukotriene B4 level in plasma of adjuvant-induced arthritis tested animals.Conclusion: The presented update showed that esculetin may be useful as a tool in regulating the mechanism and physiological functions of the inflammatory mediators and enzyme. Hence, the presented review work may be considered as a scientific proof for the development of an attractive drug candidate for the patient with rheumatoid arthritis.